14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.315 $0.440 Thursday, 25th Apr 2024 GLMD stock ended at $0.393. This is 1.88% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 9.69% from a day low at $0.360 to a day high of $0.395.
90 days $0.300 $0.466
52 weeks $0.260 $5.63

Historical Galmed Pharmaceuticals Ltd. prices

Date Open High Low Close Volume
Feb 13, 2024 $0.361 $0.466 $0.350 $0.380 1 173 661
Feb 12, 2024 $0.380 $0.380 $0.346 $0.370 41 569
Feb 09, 2024 $0.350 $0.370 $0.345 $0.360 19 557
Feb 08, 2024 $0.360 $0.370 $0.340 $0.357 33 982
Feb 07, 2024 $0.410 $0.410 $0.345 $0.365 149 067
Feb 06, 2024 $0.378 $0.390 $0.352 $0.355 25 537
Feb 05, 2024 $0.380 $0.400 $0.350 $0.362 156 342
Feb 02, 2024 $0.400 $0.460 $0.370 $0.381 191 217
Feb 01, 2024 $0.360 $0.406 $0.351 $0.404 149 928
Jan 31, 2024 $0.390 $0.390 $0.370 $0.375 25 551
Jan 30, 2024 $0.385 $0.387 $0.351 $0.386 56 744
Jan 29, 2024 $0.379 $0.390 $0.370 $0.380 16 711
Jan 26, 2024 $0.400 $0.400 $0.365 $0.379 13 318
Jan 25, 2024 $0.391 $0.399 $0.365 $0.365 46 356
Jan 24, 2024 $0.400 $0.400 $0.370 $0.370 49 706
Jan 23, 2024 $0.370 $0.384 $0.350 $0.378 31 094
Jan 22, 2024 $0.370 $0.370 $0.340 $0.354 36 488
Jan 19, 2024 $0.380 $0.390 $0.320 $0.337 154 869
Jan 18, 2024 $0.400 $0.400 $0.380 $0.380 17 551
Jan 17, 2024 $0.400 $0.406 $0.351 $0.384 169 812
Jan 16, 2024 $0.453 $0.460 $0.400 $0.408 90 246
Jan 12, 2024 $0.440 $0.455 $0.431 $0.454 64 320
Jan 11, 2024 $0.440 $0.457 $0.420 $0.450 70 233
Jan 10, 2024 $0.450 $0.460 $0.438 $0.457 36 630
Jan 09, 2024 $0.430 $0.450 $0.423 $0.449 25 150
Click to get the best stock tips daily for free!

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... GLMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT